These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26568174)

  • 1. The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety.
    Ihaddadene R; Carrier M
    Expert Opin Drug Saf; 2016 Jan; 15(1):65-74. PubMed ID: 26568174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of anticoagulant treatment in cancer patients.
    Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
    Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients.
    Pathak R; Karmacharya P; Giri S; Poudel DR; Aryal MR; Bhatt VR; Shamoun FE; Pandit A
    Blood Coagul Fibrinolysis; 2015 Sep; 26(6):635-42. PubMed ID: 26236940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
    Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
    J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bariatric venous thromboembolism prophylaxis: an update on the literature.
    Hamadi R; Marlow CF; Nassereddine S; Taher A; Finianos A
    Expert Rev Hematol; 2019 Sep; 12(9):763-771. PubMed ID: 31219356
    [No Abstract]   [Full Text] [Related]  

  • 10. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
    Harrington DW
    Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin dosing for venous thromboembolism prophylaxis in obese hospitalized patients: An observational study.
    Patanwala AE; Seaman SM; Kopp BJ; Erstad BL
    Thromb Res; 2018 Sep; 169():152-156. PubMed ID: 30071480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism.
    Barsam SJ; Patel R; Arya R
    Br J Haematol; 2013 Jun; 161(6):764-77. PubMed ID: 23560605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
    Walker CK; Sandmann EA; Horyna TJ; Gales MA
    Ann Pharmacother; 2017 Apr; 51(4):323-331. PubMed ID: 28228055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke.
    Hackett CT; Ramanathan RS; Malhotra K; Quigley MR; Kelly KM; Tian M; Protetch J; Wong C; Wright DG; Tayal AH
    Thromb Res; 2015 Feb; 135(2):249-54. PubMed ID: 25554497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis.
    Al Yami MS; Silva MA; Donovan JL; Kanaan AO
    J Thromb Thrombolysis; 2018 Jan; 45(1):36-47. PubMed ID: 29043538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism chemoprophylaxis regimens in trauma and surgery patients with obesity: A systematic review.
    Shaikh S; Boneva D; Hai S; McKenney M; Elkbuli A
    J Trauma Acute Care Surg; 2020 Apr; 88(4):522-535. PubMed ID: 31688792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
    Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
    Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis.
    Shorr AF; Jackson WL; Sherner JH; Moores LK
    Chest; 2008 Jan; 133(1):149-55. PubMed ID: 17925410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.